US5770396A
(en)
*
|
1992-04-16 |
1998-06-23 |
The United States Of America As Represented By The Department Of Health And Human Services |
Isolation characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin E
|
ATE264388T1
(de)
*
|
1992-09-24 |
2004-04-15 |
Tanox Biosystems Inc |
Umgestaltete monoklonale antikörper gegen ein immunglobulinisotyp
|
US6066718A
(en)
*
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US5958708A
(en)
*
|
1992-09-25 |
1999-09-28 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
US20020193575A1
(en)
|
1993-09-07 |
2002-12-19 |
Smithkline Beecham P.L.C. |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5928904A
(en)
*
|
1993-09-07 |
1999-07-27 |
Smithkline Beecham Corporation |
DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
US5914110A
(en)
*
|
1993-09-07 |
1999-06-22 |
Smithkline Beecham Corporation |
Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
|
GB9324013D0
(en)
*
|
1993-11-22 |
1994-01-12 |
3I Res Expl Ltd |
Polypeptides
|
MX9602818A
(es)
*
|
1994-01-18 |
1997-06-28 |
Genentech Inc |
Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
|
US20040197326A1
(en)
*
|
1995-07-27 |
2004-10-07 |
Genentech, Inc. |
Method for treatment of allergic asthma
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
ATE230417T1
(de)
*
|
1996-03-01 |
2003-01-15 |
Novartis Erfind Verwalt Gmbh |
Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
|
US5958880A
(en)
*
|
1996-12-19 |
1999-09-28 |
Heska Corporation |
Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
|
US7122636B1
(en)
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
US6172213B1
(en)
|
1997-07-02 |
2001-01-09 |
Genentech, Inc. |
Anti-IgE antibodies and method of improving polypeptides
|
US5994511A
(en)
*
|
1997-07-02 |
1999-11-30 |
Genentech, Inc. |
Anti-IgE antibodies and methods of improving polypeptides
|
US6057127A
(en)
*
|
1998-01-29 |
2000-05-02 |
Heska Corporation |
Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
|
US6504013B1
(en)
*
|
2000-02-01 |
2003-01-07 |
Idexx Laboratories, Inc. |
Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody
|
US7393529B2
(en)
*
|
1998-04-09 |
2008-07-01 |
Idexx Laboratories, Inc. |
Methods and compositions for inhibiting binding of IgE to a high affinity receptor
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
US6299875B1
(en)
*
|
1998-06-04 |
2001-10-09 |
Panacea Pharmaceuticals, Llc |
Methods to block IGE binding to cell surface receptors of mast cells
|
TWI227241B
(en)
|
1998-06-20 |
2005-02-01 |
United Biomedical Inc |
IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
|
MXPA01008612A
(es)
*
|
1999-02-25 |
2003-06-24 |
Smithkline Beecham Biolog |
Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos.
|
US6889145B1
(en)
|
2000-03-15 |
2005-05-03 |
Northwestern University |
Three-dimensional model of a Fc region of an IgE antibody and uses thereof
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
JP4460302B2
(ja)
|
2002-02-05 |
2010-05-12 |
ジェネンテック インコーポレイテッド |
タンパク質精製法
|
WO2003102132A2
(en)
|
2002-04-26 |
2003-12-11 |
Genetech, Inc. |
Non-affinity purification of proteins
|
US7365168B2
(en)
|
2002-10-15 |
2008-04-29 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
US20060034845A1
(en)
|
2002-11-08 |
2006-02-16 |
Karen Silence |
Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
|
EP1900753B1
(en)
|
2002-11-08 |
2017-08-09 |
Ablynx N.V. |
Method of administering therapeutic polypeptides, and polypeptides therefor
|
US9320792B2
(en)
|
2002-11-08 |
2016-04-26 |
Ablynx N.V. |
Pulmonary administration of immunoglobulin single variable domains and constructs thereof
|
EP2267032A3
(en)
|
2002-11-08 |
2011-11-09 |
Ablynx N.V. |
Method of administering therapeutic polypeptides, and polypeptides therefor
|
JP4869064B2
(ja)
|
2003-04-04 |
2012-02-01 |
ジェネンテック, インコーポレイテッド |
高濃度抗体及びタンパク質製剤
|
EP3722309A1
(en)
|
2003-07-28 |
2020-10-14 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
US7655229B2
(en)
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
US7662926B2
(en)
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
TWI391399B
(zh)
|
2005-05-25 |
2013-04-01 |
Hoffmann La Roche |
測定溶離多肽之鹽濃度之方法
|
US8080249B2
(en)
*
|
2005-06-30 |
2011-12-20 |
Risk Glifford G |
Methods to treating chronic obstructive pulmonary disease
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008091740A2
(en)
|
2007-01-22 |
2008-07-31 |
Genentech, Inc. |
Polyelectrolyte precipitation and purification of antibodies
|
AR065368A1
(es)
|
2007-02-15 |
2009-06-03 |
Astrazeneca Ab |
Anticuerpos para moleculas de ige
|
DK3597659T3
(da)
|
2007-07-09 |
2023-04-03 |
Genentech Inc |
Forhindring af disulfidbindingsreduktion under rekombinant produktion af polypeptider
|
PE20120259A1
(es)
|
2007-08-09 |
2012-04-04 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
ES2609280T3
(es)
|
2007-08-23 |
2017-04-19 |
Lsi Medience Corporation |
Inhibidor de reacción no específica
|
PL2565206T3
(pl)
|
2007-10-30 |
2017-08-31 |
Genentech, Inc. |
Oczyszczanie przeciwciał za pomocą chromatografii kationowymiennej
|
US8999702B2
(en)
|
2008-06-11 |
2015-04-07 |
Emd Millipore Corporation |
Stirred tank bioreactor
|
ES2527943T5
(es)
|
2008-08-14 |
2019-03-07 |
Genentech Inc |
Métodos para eliminar un contaminante usando cromatografía de membrana de intercambio iónico de desplazamiento de proteínas
|
US20100068210A1
(en)
|
2008-09-10 |
2010-03-18 |
Ji Junyan A |
Compositions and methods for the prevention of oxidative degradation of proteins
|
SG171764A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Purification of proteins
|
SG171446A1
(en)
|
2008-12-16 |
2011-07-28 |
Millipore Corp |
Stirred tank reactor and method
|
US8435488B2
(en)
|
2009-02-27 |
2013-05-07 |
Genentech, Inc. |
Methods and compositions for protein labelling
|
RU2011140498A
(ru)
|
2009-03-06 |
2013-04-20 |
Дженентек, Инк. |
Препарат антител
|
ES2793348T3
(es)
|
2009-08-11 |
2020-11-13 |
Hoffmann La Roche |
Producción de proteínas en medios de cultivo celular libres de glutamina
|
BR112012004697B8
(pt)
|
2009-09-01 |
2021-05-25 |
Genentech Inc |
método para purificar um polipeptídeo compreendendo uma região ch2/ch3
|
MX354867B
(es)
|
2010-03-22 |
2018-03-23 |
Genentech Inc Star |
Composiciones y métodos útiles para estabilizar formulaciones que contienen proteína.
|
WO2011139718A1
(en)
|
2010-05-03 |
2011-11-10 |
Genentech, Inc. |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
CN107312062B
(zh)
|
2010-05-17 |
2021-03-16 |
Emd密理博公司 |
用于纯化生物分子的刺激响应性聚合物
|
DK2576580T3
(en)
|
2010-05-28 |
2016-10-17 |
Hoffmann La Roche |
LOWERING THE lactate AND INCREASE polypeptide production by downregulation of the expression of lactate dehydrogenase, and PYRUVATDEHYDROGENASEKINASE
|
AU2011270828B2
(en)
|
2010-06-24 |
2015-09-24 |
Genentech, Inc. |
Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations
|
CA2808185A1
(en)
|
2010-08-13 |
2012-02-16 |
Genentech, Inc. |
Antibodies to il-1.beta. and il-18, for treatment of disease
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
UA112062C2
(uk)
|
2010-10-04 |
2016-07-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Cd33-зв'язувальний агент
|
JP6027104B2
(ja)
|
2011-07-08 |
2016-11-16 |
イー・エム・デイー・ミリポア・コーポレイシヨン |
使い捨てバイオテクノロジー方法のための改良されたデプスフィルター
|
EP2791169B1
(en)
|
2011-12-16 |
2017-07-19 |
Synthon Biopharmaceuticals B.V. |
Compounds and methods for treating inflammatory diseases
|
TR201815709T4
(tr)
|
2011-12-22 |
2018-11-21 |
Hoffmann La Roche |
İyon değişim membranı kromatografisi.
|
MX365947B
(es)
|
2012-03-27 |
2019-06-19 |
Genentech Inc |
Operaciones de cosecha mejoradas para proteinas recombinadas.
|
BR112014028600B1
(pt)
|
2012-05-18 |
2022-11-22 |
Genentech, Inc |
Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação
|
GB2503883A
(en)
*
|
2012-07-09 |
2014-01-15 |
King S College London |
Variant IgE with reduced affinity to CD23
|
US9393327B2
(en)
|
2012-12-19 |
2016-07-19 |
Genentech, Inc. |
Methods and compositions for radiohalogen protein labeling
|
CN106686977B
(zh)
|
2014-07-09 |
2022-03-25 |
豪夫迈·罗氏有限公司 |
Ph调整以改善细胞库的解冻复苏
|
BR112018070139A2
(pt)
|
2016-03-29 |
2019-02-05 |
Geltor Inc |
expressão de proteínas em bactérias gram-negativas em que a razão entre o volume periplasmático e o volume citoplasmático é entre 0,5:1 e 10:1
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
BR112019012686A2
(pt)
|
2016-12-22 |
2019-11-19 |
Genentech Inc |
métodos e formulações para a redução do tempo de reconstituição de polipeptídeos liofilizados
|
AU2018205484A1
(en)
*
|
2017-01-06 |
2019-08-01 |
Sixal, Inc. |
Therapeutic anti-lgE antibodies and methods and compositions thereof
|
EP3635093A1
(en)
|
2017-06-08 |
2020-04-15 |
Polpharma Biologics S.A. |
Improved methods of cell culture
|
US11180541B2
(en)
|
2017-09-28 |
2021-11-23 |
Geltor, Inc. |
Recombinant collagen and elastin molecules and uses thereof
|
KR20200085820A
(ko)
|
2017-11-07 |
2020-07-15 |
휴비트 제노믹스 가부시키가이샤 |
IgE 클래스에 특이적인 면역 반응의 억제 효과를 통한 영아기의 알레르기 소인 획득을 저지하는 방법
|
EA202092904A1
(ru)
|
2018-07-03 |
2021-04-22 |
Бристол-Маерс Сквибб Компани |
Способы получения рекомбинантных белков
|
EP3864127A1
(en)
|
2018-10-10 |
2021-08-18 |
Boehringer Ingelheim International GmbH |
Method for membrane gas transfer in high density bioreactor culture
|
TW202102266A
(zh)
|
2019-04-01 |
2021-01-16 |
美商建南德克公司 |
用於穩定含有蛋白質之配方之組合物及方法
|
CA3136691A1
(en)
|
2019-04-12 |
2020-10-15 |
Geltor, Inc. |
Recombinant elastin and production thereof
|
EP4007808A1
(en)
|
2019-08-01 |
2022-06-08 |
Bristol-Myers Squibb Company |
Methods of improving protein productivity in fed-batch cell cultures
|
IL299747A
(en)
|
2020-07-10 |
2023-03-01 |
Shanghai Jemincare Pharmaceutical Co Ltd |
Transgenic antibody against IGE and its application
|
US20230357815A1
(en)
|
2020-09-22 |
2023-11-09 |
Bristol-Myers Squibb Company |
Methods for increasing productivity of therapeutic proteins
|
WO2023015234A1
(en)
|
2021-08-05 |
2023-02-09 |
Bristol-Myers Squibb Company |
Cell culture methods for producing therapeutic proteins
|
WO2023049687A1
(en)
|
2021-09-21 |
2023-03-30 |
Bristol-Myers Squibb Company |
Methods of controlling the level of dissolved oxygen (do) in a solution comprising a recombinant protein in a storage container
|